Skip to content

Mitochondrial Peptide Research

MOTS-c vs SS-31: Mitochondrial Peptide Research Compared

MOTS-c and SS-31/elamipretide are both discussed as mitochondrial peptide research areas, but they differ in origin, mechanism and clinical-development status.

Evidence status

MOTS-c evidence is emerging across mechanistic, animal and early human biology work; SS-31/elamipretide has a distinct clinical-development literature.

What MOTS-c is

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA and studied in metabolism, stress responses and mitochondrial signalling.

What SS-31 / elamipretide is

SS-31, also known as elamipretide, is a mitochondria-targeting tetrapeptide with a distinct clinical-development history.

Mitochondrial-derived peptides

MOTS-c belongs to the mitochondrial-derived peptide field. SS-31 is mitochondrial-targeting rather than mitochondrial-encoded.

Cellular-energy and oxidative-stress research

MOTS-c research often concerns AMPK-related signalling and metabolic adaptation. SS-31 research often concerns mitochondrial membrane and oxidative-stress biology.

Differences between MOTS-c and SS-31

They differ in origin, sequence, mechanism and development status. They should not be treated as interchangeable.

Animal evidence

Animal evidence exists for both areas, but models and endpoints differ.

Human evidence

Human evidence for MOTS-c is emerging. Elamipretide has been studied in more formal clinical-development settings for specific conditions.

FAQs

Is SS-31 the same as MOTS-c?

No.

Are both mitochondrial peptides?

They are both mitochondrial-related peptide topics, but in different ways.

Scientific references

Scientific references should be checked against primary literature and review articles for the exact compound, model and endpoint being discussed. This article avoids converting cellular or animal findings into human efficacy claims.